Literature DB >> 1985300

Tropical spastic paraparesis-like illness occurring in a patient dually infected with HIV-1 and HTLV-II.

J R Berger1, A Svenningsson, S Raffanti, L Resnick.   

Abstract

We describe a 34-year-old man from southern Florida with a history of intravenous drug use, dually infected with human immunodeficiency virus type 1 (HIV-1) and human T-lymphotropic virus type II (HTLV-II), who developed a myelopathy clinically indistinguishable from HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP). This myelopathy was characterized by spastic lower extremity weakness, distal paresthesias, sensory loss with a discrete thoracic level to pinprick, back pain, impotence, and sphincter disturbances. Nerve conduction studies revealed an associated mixed axonal and demyelinative neuropathy. Despite a lack of response to 10 months of zidovudine therapy, the myeloneuropathy improved dramatically 2 years after its onset in the absence of any therapeutic intervention.

Entities:  

Mesh:

Year:  1991        PMID: 1985300     DOI: 10.1212/wnl.41.1.85

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  7 in total

1.  HTLV-II infection in the Western United States.

Authors:  B Hjelle
Journal:  West J Med       Date:  1994-06

2.  PDZ binding motif of HTLV-1 Tax promotes virus-mediated T-cell proliferation in vitro and persistence in vivo.

Authors:  Li Xie; Brenda Yamamoto; Abdelali Haoudi; O John Semmes; Patrick L Green
Journal:  Blood       Date:  2005-11-01       Impact factor: 22.113

3.  Human T-lymphotropic virus type 2 (HTLV-2) provirus in circulating cells of the monocyte/macrophage lineage in patients dually infected with human immunodeficiency virus type 1 and HTLV-2 and having predominantly sensory polyneuropathy.

Authors:  G Zehender; L Meroni; S Varchetta; C De Maddalena; B Cavalli; M Gianotto; A B Bosisio; C Colasante; G Rizzardini; M Moroni; M Galli
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

4.  Human T-cell leukemia virus type II infection among high risk groups and its influence on HIV-1 disease progression.

Authors:  M Giacomo; E G Franco; C Claudio; C Carlo; D A Anna; D Anna; F Franco
Journal:  Eur J Epidemiol       Date:  1995-10       Impact factor: 8.082

5.  Imaging of human T-lymphotropic virus type I-associated chronic progressive myeloneuropathies.

Authors:  F Alcindor; R Valderrama; M Canavaggio; H Lee; A Katz; C Montesinos; R E Madrid; R R Merino; P A Pipia
Journal:  Neuroradiology       Date:  1992       Impact factor: 2.804

6.  Phosphorylation regulates human T-cell leukemia virus type 1 Rex function.

Authors:  Matthew Kesic; Rami Doueiri; Michael Ward; O John Semmes; Patrick L Green
Journal:  Retrovirology       Date:  2009-11-17       Impact factor: 4.602

7.  Human T-cell leukemia virus type 2 post-transcriptional control protein p28 is required for viral infectivity and persistence in vivo.

Authors:  Brenda Yamamoto; Min Li; Matthew Kesic; Ihab Younis; Michael D Lairmore; Patrick L Green
Journal:  Retrovirology       Date:  2008-05-12       Impact factor: 4.602

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.